BioScrip Buys HomeChoice for $70M
The target provides antibiotic therapy, IV immune globulin and chemotherapy services to patients in their homes
BioScrip Inc. (Nasdaq: BIOS) will acquire HomeChoice Partners Inc. for $70 million in cash.
Norfolk, Va.-based HomeChoice, a majority-owned subsidiary of DaVita Healthcare Partners Inc. (NYSE: DVA), provides alternate-site pharmacy services. The company supplies antibiotic therapy, IV immune globulin and chemotherapy services to patients in their homes.
BioScrip, headquartered in Eden Prairie, Minn., provides pharmaceutical and home-care services.
The deal is expected to close in the first quarter of 2013.
For more information on related topics, visit the following: